Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Strongbridge Biopharma plc Announces Presentation of New Secondary Endpoint Data from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 2019 American Association of Clinical Endocrinologist | ||
By: Nasdaq / GlobeNewswire - 25 Apr 2019 | Back to overview list |
|
New Analysis Shows RECORLEV™ (levoketoconazole) Significantly Improved Clinician- and Patient-Reported Signs and Symptoms of Cushing’s Syndrome DUBLIN, Ireland and TREVOSE, Pa., April 25, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced the presentation of new secondary endpoint results from the Phase 3 SONICS study of RECORLEV™ (levoketoconazole) for the potential treatment of endogenous Cushing’s syndrome at the 2019 American Association of Clinical Endocrinologists (AACE) Annual Scientific and Clinical Congress, held April 24 – 28, in Los Angeles, California. “The SONICS data presented at AACE highlight Strongbridge’s commitment to developing effective treatments that translate into meaningful, real-world outcomes for patients,” said Fredric Cohen, M.D., chief medical officer of Strongbridge Biopharma. “People with Cushing’s syndrome often experience negative physical effects as well as emotional challenges brought on by the condition. These results are the first to demonstrate that treatment with RECORLEV significantly improves many of those symptoms, including acne, excess male-pattern hair growth in women, peripheral edema, and symptoms of depression. Further, these findings provide important insights from a patient perspective that may inform clinical decision-making for this population.” Highlights of Newly Presented SONICS Data at AACE:
The poster, entitled Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome: About the SONICS Study (1) Dose Titration Phase: Patients started RECORLEV at 150 mg twice daily (300 mg total daily dose) and titrated in 150 mg increments with the goal of achieving a therapeutic dose – a dose resulting in mean UFC normalization – at which point titration was stopped; (2) Maintenance Phase: The dose was fixed and should not have been changed other than for safety reasons or loss of efficacy. At the end of the six-month maintenance phase, the mean UFC response rate was measured; and (3) Extended Evaluation Phase: Patients continued on RECORLEV for another six months to evaluate long-term safety and tolerability and explore efficacy durability. About Endogenous Cushing’s Syndrome About Strongbridge Biopharma Contacts: Corporate and Media Relations Investor Relations Europe: USA |
||
|
||
Copyright 2019 Nasdaq / GlobeNewswire | Back to overview list |